Peculiarities of hemostasis changes under the influence of different regimens of antiplatelet therapy in patients with Q-wave myocardial infarction
DOI:
https://doi.org/10.14739/2310-1237.2014.3.36635Keywords:
Myocardial Infarction, Protein C, von Willebrand Factor, Adhesion MoleculesAbstract
Aim. In order to study the influence of different regimens of antiplatelet therapy on the state of coagulation and aggregation hemostasis, intracardiac hemodynamics, incidence of post-infarction aneurysm and thrombus formation in the left ventricular cavity in patients with Q-wave myocardial infarction after thrombolysis, 123 people were examined.
Methods and results. All participants underwent echocardiography, the study of coagulation and aggregation hemostasis, levels of protein C, von Willebrand factor and adhesion molecules sVCAM-1 were determined.
Conclusion. Under the influence of the treatment reduction in aggregation and procoagulant activity of blood serum and activation of fibrinolytic processes were revealed, accompanied by improvement of left ventricular pumping and systolic function, diastolic dysfunction transformation from impaired relaxation into pseudonormal type.
References
Grinstein, Y. I., Savchenko, E. A., Filonenko, I. V., Grinstein, I. Yu., Savchenko, A. A. (2008). Zilt u pacientov s aterosklerozom koronarnykh arterij posle aortokoronarnogo shuntirovaniya. Predvaritelnye rezultaty otkrytogo, randomizirovannogo, sravnitelnogo issledovaniya ZEVS [Zyllt in coronary atherosclerosis patients after coronary artery bypass graft surgery. Preliminary results of an open, randomized, comparative ZEUS Study]. Kardiovaskulyarnaya terapiya i profilaktika, 7(6), 43–49. [in Russian].
Dzyak, G. V., Koval`, E. A., Ivanov, A. P., & Shevcova, A. I. (2007). Tip degradacii fibronektina kak novyj dopolnitelnyj faktor riska tromboticheskikh i gemorragicheskikkh oslozhnenij ostrogo infarkta miokarda s zubcom Q [Fibronectin degradation type as new additional risk factor of thrombotic and hemorrhagic complications of acute Q-wave myocardial infarction]. Sertse i sudyny, 1(17), 13–18. [in Ukrainian].
Kovalenko, V. M., & Kornatskyj, V. M. (Eds). (2013) Regionalni medyko-socialni problemy khvorob systemy krovoobihu. Dynamika ta analiz. Analityko-statystychnnyi posibnyk [Regional medical and social problems of cardiovascular system diseases. Dynamics and analysis. Analytic statistic textbook]. Kyiv. [in Ukrainian].
Syvolap, V. D., & Kyselov, S. M. (2014) Sostoyanie sistemy gemostaza i remodelirovanie serdca u bolnych Q-infarktom miokarda s ostroj anevrizmoj i pristenochnym trombom levogo zheludochka [Hemostatic system condition and heart remodeling in patients with Q-wave myocardial infarction with acute aneurysm and thrombus of left ventricle]. Zaporozhskij medicinskij zhurnal, 1(82), 48–51. [in Ukrainian].
(2013). ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction 2013. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 127, e362-e425. doi: 10.1161/CIR.0b013e3182742cf6.
(2005). COMMIT collaborative group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet, 366, 1607–1621. doi:10.1016/S0140-6736(05)67660-X.
Halvorsen, S., & Huber, K. (2010) The role of fibrinolysis in the era of primary percutaneous coronary intervention. Thromb. Haemost., 105, 390 – 395. doi: 10.1160/TH10-08-0513.
Sabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., et al. (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med, 352, 1179–1189. doi: 10.1056/NEJMoa050522.
Scirica, B. M., Sabatine, M. S., Morrow, D. A., Gibson, C. M., Murphy, S., Wiviott, A. S. D., et al. (2006). The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction. The ECG CLARITY-TIMI 28 study. J. Am. Coll. Cardiol., 48, 1, 37–42. doi:10.1016/j.jacc.2006.02.052.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).